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Hereditary hyperekplexia is caused by disinhibition of motoneu-
rons resulting from mutations in the ionotropic receptor for the
inhibitory neurotransmitter glycine (GlyR). To study the patho-
mechanisms involved in vivo, we generated and analyzed
transgenic mice expressing the hyperekplexia-specific domi-
nant mutant human GlyR 1 subunit 271Q. Tg271Q transgenic
mice, in contrast to transgenic animals expressing a wild-type
human 1 subunit (tg271R), display a dramatic phenotype sim-
ilar to spontaneous and engineered mouse mutations express-
ing reduced levels of GlyR. Electrophysiological analysis in the
ventral horn of the spinal cord of tg271Q mice revealed a
diminished GlyR transmission. Intriguingly, an even larger re-
duction was found for GABAA-receptor-mediated inhibitory
transmission, indicating that the expression of this disease
gene not only affects the glycinergic system but also leads to a
drastic downregulation of the entire postsynaptic inhibition.
Therefore, the transgenic mice generated here provide a new
animal model of systemic receptor interaction to study inherited
and acquired neuromotor deficiencies at different functional
levels and to develop novel therapeutic concepts for these
diseases.
Key words: hyperekplexia; transgenic mouse model; neuro-
motor phenotype; glycine receptor; GABAA receptor; impaired
postsynaptic inhibition
Human startle disease, or hereditary hyperekplexia, is a rare
inborn neuromotor disease and one of the few examples of a
syndrome linked to a defined mutation in a neuroreceptor ion-
channel subunit gene (Andrew and Owen, 1997). The disease is
characterized by an exaggerated startle reflex (i.e., overreaction
to unexpected stimuli with myoclonic jerks and stiffness), often
resulting in uncontrolled falling. In addition, uninduced nocturnal
convulsive seizures occur occasionally. Enhanced startle reac-
tions can already be detected in newborns in whom generalized
hypertonia has also been observed (Suhren et al., 1966). Electro-
myographic studies reveal distinct overexcitability and diminished
inhibition in patients with hyperekplexia (Matsumoto et al., 1992;
Floeter et al., 1996).
The disease has been shown to result from mutations in the 1
subunit of the strychnine-sensitive glycine receptor (GlyR)
(Shiang et al., 1993), which is the major inhibitory chloride
channel in the spinal cord and the brainstem (Betz, 1992). In the
adult mammal, the GlyR is composed of three copies of the
ligand-binding 1 subunit and two copies of the structural 
subunit, which targets the GlyR to the postsynaptic membrane by
interacting with the anchoring protein gephyrin (Meyer et al.,
1995; Feng et al., 1998).
The properties of mutant subunits have been studied in detail
in vitro and in transfected heterologous cell systems (Langosch et
al., 1994; Rajendra et al., 1994; Laube et al., 1995). However, it
emerged from the study of mouse mutants with GlyR defects that
in vivo mouse models were indispensable in understanding the
pathomechanisms in patients. For example, although functional
1 subunit homomers are assembled in reconstituted Xenopus
oocytes and in transfected non-neuronal tissue culture (Langosch
et al., 1994; Rajendra et al., 1994), in the adult rodent the 
subunit is essential for the formation of complexes containing
functional 1 subunit (Becker et al., 1992, 2000; Hartenstein et al.,
1996). In addition, in vivo models are necessary to study possible
interactions between different neurotransmitter systems in
healthy and diseased states because the complexity of these
interactions is not known and is therefore difficult to reconstitute.
In patients with startle disease, such interactions were suggested
by the therapeutic success of treatment with agonists of the other
major inhibitory neurotransmitter receptor, the GABAA receptor
(Ryan et al., 1992; Stayer and Meinck, 1998).
Although several genetically recessive mouse mutants exist, we
generated a mouse model that more closely resembles a human
dominant GlyR disease. The mutant human gene used to gener-
ate transgenic mice is associated with the most frequent geneti-
cally dominant form of hereditary hyperekplexia in humans
(Shiang et al., 1993; Andrew and Owen, 1997). The mutation
substitutes a glutamine for an arginine at position 271 in the
extracellular domain of the GlyR 1 molecule; it has been shown
in vitro and in tissue culture to strongly reduce receptor binding to
the natural ligand glycine, although it does not significantly affect
receptor binding to the antagonist strychnine (Langosch et al.,
1994; Rajendra et al., 1994). We received transgenic animals
displaying a characteristic neuromotor phenotype attributable to
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mutant transgene expression. Biochemical analyses confirmed the
in vitro data, and electrophysiological studies revealed a novel
interaction between the different inhibitory neurotransmitter sys-
tems in vivo.
MATERIALS AND METHODS
Constructs and transgenic mice. A SalI-fragment of 1.7 kb containing the
human GlyR-subunit cDNA (Grenningloh et al., 1990b) was cloned into
the unique XhoI site of a Thy-1 expression vector (Moechars et al., 1996).
An EcoRI/PvuI fragment was used for microinjections into zygotes of
C57BL/6/DBA/2 females and C57BL/6 males to generate tg271R lines.
An analogous fragment in which codon 271 was mutated CGA to CAA
(R3Q) was used to generate the tg271Q founders. Founders were bred
with C57BL/6 to derive the experimental lines.
Expression analysis. Reverse transcriptase (RT)-PCR analysis on cor-
tex and brainstem RNA was done using Superscript II (Invitrogen, Grand
Island, NY) according to the manufacturer’s instructions. GlyR 1-
specific primers recognized endogenous and transgenic cDNA: 5-
CTCATCTTTGAGTGGCAGGA-3 and 5-GCATCCATGTTGATCC-
AGAA-3. The ratio of the GlyR 1-specific to the -actin-specific signal
was determined. Data (Fig. 1 B) are given as means  SD. Statistical
analysis was performed using ANOVA with the Bonferroni post hoc test.
In situ hybridization was performed on sagittal sections of paraffin-
embedded brains from mice of different genotypes. In vitro 35S-labeled
RNA transcripts from a 0.5 kb XhoI /SalI fragment of the human cDNA
were used as a probe. Detection of transcripts was performed with LM-1
Photoemulsion (Amersham Biosciences, Arlington Heights, IL).
Ligand binding. Glycine-displaceable binding of 3H-strychnine (Du-
Pont NEN, Boston, MA) to crude membrane fractions was measured in
triplicate as described previously (Becker et al., 1986). For radioligand
displacement, 18 nM 3H-strychnine was used. Data in Figure 2 are given
as means  SD. Statistical analysis was performed using ANOVA with the
Bonferroni post hoc test (Fig. 2A) or the Mann–Whitney U test (Fig. 2B).
Receptor autoradiography. Frozen sections of brain were used for ra-
dioligand binding assays. Sections were incubated with 4 nM 3H-
strychnine alone and in the presence of unlabeled strychnine and glycine.
For the benzodiazepine binding, 10 nM 3H-RO15-4513 (kindly provided
by D. Benke, Institute of Pharmacology, University of Zu¨rich, Zu¨rich,
Switzerland) in the absence or presence of flumazenil was used. A
3H-sensitive imager plate with the Fujifilm Fluorescent image analyzer
FLA2000 (Tokyo, Japan) was used for signal detection.
Phenotype anal ysis. Qualitatively, motor deficiencies in the animals
were recognized with handling. In particular, tg271Q-300 as well as the
homozygous tg271Q-382 and tg271Q-331 mice could be readily iden-
tified by a trained observer: When picked up by the tail they displayed
obvious vibrations and/or showed the “hind feet clenching” pheno-
type. Sudden noise induced them to jump up and fall into tremor
episodes, lasting for variable times even when held by the tail. Quan-
titative analysis was done as follows: Righting time was determined
after bringing the animals into a supine position as described previ-
ously (Hartenstein et al., 1996; Becker et al., 2000) by twisting their
tails. Tremor recording was performed by fixing mice by their tails to
an F30 force transducer (Type 372) connected to a bridge amplifier
(Type 336; both from Hugo Sachs Elektronik, March-Hugstetten,
Germany). Electric signals were recorded by a Voltcraft Scope Card
220 (Voltcraft, Hirschau, Germany).
Slice preparation. Mice (both sexes) that were 14 to 21 d of age were
anesthetized with ether and decapitated. The lumbar segments of the
spinal cord were isolated and transferred to ice-cold standard external
solution that contained (in mM): 120 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2,
1.25 NaH2PO4, 26 NaHCO3, 5 HEPES, and 15 glucose, pH 7.4 (310
mOsm). The dorsal side of the spinal cord was glued onto a gelatin block
and 250-m-thick transverse slices were cut with a vibratome (Campden
Instruments, Loughborough, UK). Slices were incubated for 1.5–7 hr
after preparation in standard external solution at 32°C and bubbled
continuously with carbogene (95% O2 and 5% CO2).
Electrophysiolog ical recordings. Electrophysiological recordings were
made from visually identified large-diameter neurons (20 m) in the
ventral horn, presumptive -motoneurons. They were visualized with the
infrared gradient contrast technique (Dodt and Zieglgansberger, 1994)
and monitored by a video microscopic system mounted on an upright
microscope (Zeiss Axioskop FS, Jena, Germany; Infracontrast; Luigs &
Neumann, Ratingen, Germany; video camera CF 8/1; Kappa Messtech-
nik, Gleichen, Germany). Slices were kept in position by a nylon mesh
fixed to a U-shaped platinum wire. They were continuously superfused
by standard external solution bubbled with carbogene. The experiments
were performed at room temperature (20  2°C). Patch pipettes were
pulled from borosilicate glass capillaries (Kimax 51; Kimble, Vineland,
NJ) by a DMZ Universal puller (Zeitz, Munich, Germany) and tip-
polished by default. The pipette resistance ranged between 3 and 5 M
when filled with standard internal solution (in mM: 130 potassium glu-
conate, 20 KCl, 0.05 EGTA, 3 Na2ATP, 0.1 Na3GTP, 10 HEPES, pH
7.30) (290 mOsm). Lidocaine N-ethyl bromide (QX-314) (5 M) was
added to the internal solution to block voltage-activated sodium currents
in the recorded neuron. Postsynaptic currents (PSCs) were elicited via an
ipsilaterally placed glass electrode (cathode, Kimax 51, inner tip diam-
eter 2 m), at a circumradial distance of 50 m to the recording
electrode, filled with 1 mM NaCl. Electrical stimulation (100 sec; 1–5 V;
AM Systems, Everett, MA) occurred at intervals of 10 sec. Recordings
were performed in the whole-cell configuration of the patch-clamp tech-
nique with an EPC-7 patch-clamp amplifier (List Elektronik, Pfungstadt,
Germany). Currents were monitored and stored with the Pulse Program
(Heka Elektronik, Lambrecht /Pfalz, Germany) on a Macintosh Quadra
950 computer, linked to an ITC-16 interface (InstruTech, Port Wash-
ington, NY). To facilitate the establishment of a seal on the selected
neuron, the external CaCl2 concentration was augmented to 3 mM during
Figure 1. Transgene expression in GlyR transgenic mice is shown. A,
Transgene constructs used. The human GlyR cDNAs (open bar) were
cloned in a murine genomic Thy-1 gene construct in which a region from
exon 2 to exon 4 was deleted (Moechars et al., 1996) to confer neuron-
specific expression (hatched bars, exon sequences; solid gray bars, intron
sequences). The hyperekplexia-specific point mutation is marked by an
arrow and an asterisk. B, Semiquantitative RT-PCR of brainstem and
spinal cord (sc, black bars) and forebrain ( fb, hatched bars) of different
mouse lines. The expression of tg271Q-300 in spinal cord was set as 100%.
The differences in spinal cord between wt and tg271Q-300 and tg271R-
783 mice are significant (asterisks; p  0.05) C, D, In situ hybridization of
sagittal brain sections with GlyR -specific RNA probes of a wt (C) and
a tg271Q-300 (D) animal. E, 3H-strychnine binding to sagittal sections of
wt (lef t), tg271Q-300 (center), and tg271R-783 (right) mice.
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this phase. After breaking in, the concentration was lowered again to 2
mM. Currents were sampled at a frequency of 20 kHz and filtered at 3
kHz. Recordings were analyzed using the IgorPro 2.01 program (Wave-
Metrics Inc., Lake Oswego, OR). Drug solutions were applied by bath
perfusion at a rate of 3–5 ml/min. All data in Figure 6 are given as
means  SEM. Statistical analysis was performed using the Mann–
Whitney U test.
Chemicals. All inorganic salts, glucose, EGTA, Na2ATP, Na3GTP,
potassium gluconate, QX-314, kynurenic acid, strychnine, and bicucul-
line were purchased from Sigma (St. Louis, MO). HEPES was purchased
from Calbiochem-Novabiochem (Bad Soden, Germany). CNQX and
AP-5 were obtained from Tocris Cookson (Bristol, UK). Bicuculline was
solved in DMSO. The final concentration of the solvent in the experi-
ments was 0.05%.
RESULTS
Human GlyR1 subunits form chimeric receptors in
transgenic mice
Two constructs were made (Fig. 1A), in which the human GlyR
1 cDNA [mutated (271Q) or unmutated (271R)] was under the
control of the brain-specific Thy-1 promoter (Moechars et al.,
1996). Four tg271Q strains and 10 tg271R control strains with
different levels of total transgene expression in neuronal tissue
were derived (data not shown); four of each were kept for
additional analysis. RT-PCR was performed to examine trans-
gene expression in spinal cord and forebrain relative to that of the
endogenous gene (Fig. 1B). The primers used for this analysis
amplified both the transgenic human and the endogenous murine
GlyR 1-subunit mRNA. Compared with samples from the wild-
type (wt) mice (lef t), we found strongly enhanced GlyR 1
mRNA levels in the spinal cord, indicating expression of the
transgene in addition to the endogenous gene. In the forebrain,
the endogenous GlyR 1-subunit mRNA is hardly expressed;
therefore, the GlyR 1 mRNA detected in the transgenic mice
must be predominantly derived from transgenes. In situ hybrid-
ization analysis confirmed strong transgene expression in tg271Q
(Fig. 1D) and tg271R strains (data not shown) compared with wt
animals (Fig. 1C). Because, in addition to the brainstem, trans-
gene expression is also found in ectopic sites in the brain, we
investigated whether GlyR was formed there as well. In light of
the widespread endogenous expression of GlyR  mRNA in many
brain regions in which no known complex partners of this subunit
are expressed, this seemed to be possible (Grenningloh et al.,
1990a; Malosio et al., 1991). Indeed, in situ binding studies with
the competitive glycine receptor antagonist strychnine showed
ectopic ligand binding in both wt 271R and mutant 271Q lines
(Fig. 1E). This ligand-binding activity must involve recruitment
of the endogenous  subunit, because GlyR 1-subunit homo-
oligomers do not form functional receptors in vivo (Becker et al.,
1992, 2000; Hartenstein et al., 1996). Furthermore, this implies
the formation of interspecies complexes between the murine 
and the human transgene encoded (wt as well as mutant) GlyR 1
subunits. These results confirm data derived from heterologous
expression studies in vitro and from transfected cells (Langosch et
al., 1994; Rajendra et al., 1994). Strychnine binding to brainstem
appeared not to be increased in our receptor autoradiography,
which is depicted in Figure 1E. This raised the question of
4
beled strychnine ( B) or glycine (C). Asterisks indicate significance ( p 
0.05) D, Displacement of 3H-strychnine with unlabeled ligands on spinal
cord sections from different genotypes is indicated; [Note the difference in
binding in the tissue of the mutant transgenic animals (tg271Q-300 and
tg271Q-382) compared with the wt transgenic (tg271R-783) and the wt
line in the presence of 100 M glycine (bottom).]
Figure 2. GlyR ligand binding to membranes from the brainstem and
spinal cord is shown. A, Specific binding of 3H-strychnine in different
genotypes (solid line, wt; dotted line, tg271Q-300; dashed line, tg271R-783).
The asterisk at 50 nM marks a significant difference ( p  0.05) between
the wt and the transgenic strains. B, C, An 18 nM concentration of
3H-strychnine was displaced by increasing concentrations of either unla-
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whether the GlyR in the spinal cord and brainstem of the trans-
genic animals contained transgene-derived 1 subunits.
Reduced glycine affinity in the spinal cord of
tg271Q-300 mice
To measure the amount of receptor in the transgenic animals
more accurately, we used quantitative ligand-binding assays on
spinal cord membrane preparations of the strongest expressing
strains of both transgene tg271Q-300 and transgene tg271R-783
(Fig. 2A). When compared with wt animals, a slight but signifi-
cant enhancement in 3H-strychnine binding was detected, assum-
ing similar strychnine affinities of the mutated or nonmutated
human or murine 1 subunits (Langosch et al., 1994; Rajendra et
al., 1994). This is consistent with a small increment of GlyR
immunoreactivity detected in Western blot analyses (data not
shown). Thus, in spinal cord, 1-subunit-specific mRNA expres-
sion was apparently not limiting the number of membranous
receptor complexes formed. Therefore, the transgenic 1 subunits
should compete here with the endogenous ones for the limiting
component, most likely the endogenous  subunit.
If mutant transgene-derived subunits are incorporated into
spinal cord GlyR, these should show altered pharmacological
characteristics according to previous in vitro data (Langosch et al.,
1994; Rajendra et al., 1994), in which different glycine but un-
changed strychnine affinity of the mutant 1 subunits had been
demonstrated. We analyzed this by means of a ligand competition
assay, comparing spinal cord membrane preparations of tg271Q-
300 mice with those of wt animals. Figure 2B demonstrates that
3H-strychnine binding (percentage of total) was unaltered in
tg271Q transgenic mice when competing with increasing amounts
of nonradioactive strychnine. However, competition with an ex-
cess of the physiological ligand glycine revealed a significant
difference in glycine affinity in the tg271Q-300 transgenic mice
(Fig. 2C); at 1.5 and 2 log M glycine, the competition curve is
shifted.
Furthermore, we investigated ligand binding at the histological
level on tissue sections through the upper spinal cord region of
transgenic and wt animals. We included two mutant tg271Q
strains, tg271Q-300 and tg271Q-382, and one strain expressing
the wt human 1 subunit (Fig. 1B). In accordance with the
binding assays illustrated in Figure 2A, 3H-strychnine binding in
situ appeared not to be different between the different genotypes
(Fig. 2D, top two rows). In contrast to the strychnine binding, in
the animals carrying the human mutant transgene (tg271Q-300
and tg271Q-382) glycine competes less efficiently for GlyR bind-
ing compared with wt animals (Fig. 2D, bottom two rows). Mice
with the human wt transgene (tg271R-783) show glycine compe-
tition similar to nontransgenic animals, despite their high trans-
gene expression (Figs. 1B, 2D).
In summary, the ectopic mRNA expression of wt and mutant
human GlyR 1 subunit led to ectopic formation of ligand-
binding activity. In spinal cord, in which the physiological sites of
GlyR expression are located, the additional transgene-derived
mutant human 1 subunit competes for and at least partially
replaces the endogenous subunit in the GlyR complex, reducing
its ability to bind the natural ligand glycine.
Phenotypic characteristics of the tg271Q
transgenic animals
When handling the transgenic lines described here, it became
instantly apparent that tg271Q-300 animals developed spontane-
ous or handling-induced tremor episodes, which were most obvi-
ous in the extremities (Fig. 3A,B). The startle reaction was clearly
exaggerated because these animals responded noticeably by un-
controlled jerks and jumps to sudden noise or touch. Further-
more, when picked up by the tail they displayed a hind feet
clenching behavior (Fig. 3C). Their reproductive performance is
also poor. Thus far, the phenotype was very similar to that
described in the recessive mouse mutants spastic (spa)
(Kingsmore et al., 1994; Mulhardt et al., 1994) or spasmodic (spd,
spdot) (Buckwalter et al., 1994; Ryan et al., 1994; Saul et al., 1994),
which carry mutations in the GlyR - or 1-subunit gene, respec-
tively. Compared with these, the phenotype in tg271Q-300 mice
was genetically dominant because it was observed in heterozygous
transgene carriers. Homozygous tg271Q-300 animals derived
from double heterozygous crosses were not viable to adulthood.
Two strains with less 271Q transgene expression, tg271Q-382 and
tg271Q-331, (Fig. 1B) also showed this spa-like phenotype but in
an apparently gene-dosage-dependent manner (i.e., only animals
homozygous for the symptoms displayed by transgenic mice)
(Table 1). In tg271Q-354 animals, the lowest expressing 271Q
strain, no obvious phenotype was detected. Likewise, none of the
271R strains carrying the human wt transgene displayed this
phenotype, regardless of the transgene expression level.
To investigate the phenotype of tg271Q-300 mice in more
detail, we used several methods established to characterize GlyR-
Figure 3. Phenotypic characteristics of tg271Q-300 mice. A, Tremor and
disturbed righting when turned to the back. B, Handling-induced tremor,
visible at the limbs. C, Hind feet clenching when picked up by the tail.
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deficient mouse mutants (Hartenstein et al., 1996; Becker et al.,
2000). First, we measured the righting time, which can be easily
quantified and has been shown to be a reliable marker for phe-
notype strength (Hartenstein et al., 1996; Becker et al., 2000).
Animals with normal glycinergic neurotransmission instantly
right themselves when brought to a supine position. However, in
GlyR mutants this reflex is impaired, allowing for the simple
measurement of the time it takes for them to get back on their
feet. Figure 4A illustrates that the righting time in tg271Q-300
mice is dramatically increased. Compared with previous studies
of murine recessive GlyR mutants (Hartenstein et al., 1996;
Becker et al., 2000) with respect to this task, the tg271Q-300
phenotype was similar to that of spa mice with remnant GlyR
protein expression and ligand binding of 10–20% of wt in the
spinal cord and brainstem (Becker et al., 1992; Hartenstein et al.,
1996). However, it was not as strong as the phenotype recorded
from spdot (spasmodic oscillator) homozygotes (Hartenstein et al.,
1996), which carry a null mutation in the GlyR 1 gene, leading to
death within 4 weeks of birth (Buckwalter et al., 1994).
We also measured the onset of the inducible tremor in tg271Q-
300 mice (Fig. 4B): Most animals started to display this at
postnatal day 15, approximately the same time at which homozy-
gous spdot mice start to show this motor deficiency. This implies
that the mutant 1 subunit interferes specifically with the endog-
enous adult 1 isoform, which takes over glycinergic control from
the neonatal 2 isoform at approximately that time.
Finally, we recorded the tremor using an electromechanical
transducer registering the vibrations, which can be sensed when
picking up GlyR-deficient animals. We used an improved version
of a setup described previously (Becker et al., 2000), which allows
measurement of the frequency and amplitude of muscular con-
tractions during tremor. Figure 5 shows oscilloscope traces de-
rived from wt, tg271R-783, tg271Q-300, and homozygous spa
mice. The amplitude of the contractions recorded during tremor
episodes (Fig. 3B) appeared stronger in tg271Q-300 (Fig. 5D)
than in spa (Fig. 5E) animals. As with partially GlyR-deficient
homozygous spa animals but unlike completely GlyR-deficient
homozygous spdot mice, tremor in tg271Q-300 mice was not
permanent. During tremor-free periods, in which tg271Q-300
animals displayed the hind feet clenching phenotype (Fig. 3C),
movements were recorded (Fig. 5C) that were similar to those
seen in wt (Fig. 5A) or tg271R-783 (Fig. 5B) transgenic animals.
Most interestingly, the tremor frequency in both tg271Q-300 and
homozygous spa/spa mice was 25–30 Hz, which is similar to the
frequency measured in hyperekplexia or stiff-man syndrome
(SMS) (Stayer and Meinck, 1998).
Although the 271Q transgene apparently caused a disease
Table 1. Transgene expression and phenotype in different GlyR 1
transgenic mice
Transgenic
mouse lines Expression
Startle phenotype
Hind limb
disordertg / tg /
tg271Q-300  n.v.a  
tg271Q-382    
tg271Q-331  ()  
tg271Q-354    
tg271R-731    
tg271R-783    
tg271R-791    
tg271R-803    
an.v., Not viable.
Figure 4. Phenotypic analysis of tg271Q-300 animals. A, The time re-
quired to right after being turned to the back (n 	 65). B, The onset of
inducible tremor (n 	 42).
Figure 5. Tremor recordings from transgenic and control mice. Traces of
wt (A), and tg271R-783 wt transgenic (B) mice do not show any spastic
motor disorder. The tremor in tg271Q-300 mice (D) shows a larger
amplitude but a similar tremor frequency compared with homozygous spa
mice (E). C, Trace taken from a tg271Q-300 animal during a nontremor
period.
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phenotype specific for GlyR deficiencies, expression of the
tg271R construct did not. In contrast, breeding this construct into
the spdot background could rescue the lethal phenotype of this
complete loss-of-function mutation of the endogenous 1 subunit
(data not shown). This provided genetic proof that the human 1
subunit was functional in interspecies hybrid receptors in mice.
However, expression of the tg271R construct in addition to the
endogenous murine 1 subunit caused a phenotype distinct from
the one caused by the hyperekplexia transgene tg271Q (Table 1):
An initially subtle but progressive limb malcoordination appeared
most noticeable in the hind legs of adult tg271R transgenic mice.
Preliminary analysis suggests that neurodegeneration is involved
here (data not shown).
It should be noted that the transgenes were introduced into a
hybrid genetic background (C57BL/6 
 DBA/2). When compar-
ing the phenotypes of transgenic animals within and between
different litters of a particular transgenic strain, we did not notice
an apparent contribution of genetic background variations in our
animal population.
Glycine- and GABAA-receptor transmission are
impaired in the spinal cord of tg271Q-300 mice
To test whether the GlyR-dependent neuromotor inhibition in the
spinal cord is impaired in tg271Q mice, whole-cell patch-clamp
studies were performed in visually identified large-diameter neu-
rons, presumptive -motoneurons, in the ventral horn of spinal
cord slices. Tg271Q-300 mice and nontransgenic littermate controls
were 14–19 d of age (i.e., around the onset of the phenotype or
slightly later). The tissue was stimulated electrically to elicit
postsynaptic responses in the recorded motoneurons (Fig. 6A).
The total PSC could be blocked completely by a combination of 1
mM kynurenic acid, 0.5 M strychnine, and 10 M bicuculline,
indicating that the PSC was mediated only by glutamate, glycine,
and GABAA receptors in both genotypes (data not shown). The
glycinergic component of the IPSC was isolated by a combination
of 1 mM kynurenic acid and 10 M bicuculline. In accordance with
the biochemical analysis described above, this component was
strongly reduced by 69.8% in tg271Q-300 mice compared with wt
mice (n	 6 for each; p 0.05) (Fig. 6B, lef t). Interestingly, an even
larger reduction was observed for the GABAA-receptor-mediated
component of the IPSC. This component was isolated in a addi-
tional series of experiments by adding 1 mM kynurenic acid and 0.5
M strychnine to the standard external solution. A reduction of
90.9% in tg271Q-300 animals was measured in comparison with wt
animals (n 	 6 for each; p  0.05) (Fig. 6B, right). This modifica-
tion of the GABAA-receptor-mediated transmission by the expres-
sion of the mutant human GlyR 1 subunit indicated that the entire
inhibitory postsynaptic transmission is functionally downregulated
by the expression of this transgene.
GABAA receptor binding in the brain of tg271Q and
tg271R mice
To investigate whether the number of GABAA receptors was
altered in the transgenic mice, we performed binding assays with
3H-RO15-4513, a radioligand that binds to the benzodiazepine site
of most GABAA receptor complexes. Brain sections of the mice
with the two strongest mutant-transgene-expressing strains,
tg271Q-300 and tg271Q-382, as well as those with the human
wt-transgene-expressing strain tg271R-783, were analyzed in com-
parison with wt control animals (Fig. 7). No obvious difference
could be observed in the pattern and the amount of GABAA-
receptor binding between the four tested genotypes at this level of
resolution. Thus, these data are consistent with downregulation of
GABA transmission on the functional rather than on the expres-
sion level, whereby analysis at a higher resolution to determine the
intracellular distribution of the receptor remains to be done.
Figure 7. Autoradiographic studies of brains with benzodiazepine li-
gands. Distribution of 3H-RO15-4513 binding sites in the presence or
absence of flumazenil in brain sections of wt, tg271Q-783, and tg271R-783
transgenic animals are shown.
Figure 6. Electrically evoked IPSCs from spinal cord neurons are shown.
A, Representative traces from individual measurements on spinal cord
neurons of wt (lef t) and tg271Q-300 (right) mice. Top, Glycinergic compo-
nent of the IPSC. Bottom, GABAA receptor-mediated IPSC. B, Summary
of the electrophysiological data. Mean amplitudes of the glycine-receptor-
mediated (lef t) and GABAA-receptor-mediated IPSCs for tg271Q-300
animals (striped columns) and wt controls (black columns) are shown. In
tg271Q-300 animals, the glycinergic component was reduced from
331.2  124.8 pA to 100.1  23.8 pA. The GABAA-receptor-mediated
component was 4.1  3.0 pA for tg271Q-300 mice, compared with
45.0  25.4 pA in the controls. Asterisks indicate significance (p  0.05).
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DISCUSSION
The transgenic mouse model described here closely reproduces
several symptoms found in human patients with hyperekplexia,
such as inducible tremor development and exaggerated startle
response. Although in humans a causal genotype–phenotype
relationship cannot be established, our data provide formal proof
of the capacity of this human GlyR mutation to induce a domi-
nant neuromotor phenotype.
The hyperekplexia phenotype evoked in these mice is depen-
dent on mutant transgene expression. It resembles mouse mutants
with partially or completely obliterated endogenous GlyR func-
tion. Mice that topically and ectopically express a wt human GlyR
gene form ectopic ligand-binding receptors but do not show this
phenotype. In contrast, the wt transgene can rescue the mouse
GlyR 1 null mutation spd
ot, demonstrating that functional inter-
species GlyR complexes are formed in vivo and thereby support-
ing the validity of this animal model. Thus, the hyperekplexia-like
phenotype is specific for the hyperekplexia-associated mutated
GlyR transgene.
The strength of the phenotype differed between strains carry-
ing the tg271Q transgene. The strongest phenotype observed in
these lines was similar to (and in terms of tremor even stronger
than) the one described for homozygous spa mice, because of
residual ligand binding of 10–20% in wt animals. The pheno-
type appears at approximately the same time as the GlyR 1
isoform and becomes essential for glycinergic inhibition in mice.
We conclude that the mutant 1 subunit interferes specifically
with the endogenous adult 1 isoform in spinal cord, in which it
competes with endogenous 1 subunits for its essential partner 
to form GlyR complexes.
Electrophysiological analyses on spinal cord motoneurons of
tg271Q mice showed a strong reduction of the amplitude of the
glycinergic component of the IPSC (69.8%). These data validate
previous data derived in vitro and in tissue culture (Langosch et
al., 1994; Rajendra et al., 1994) and provide a physiological
explanation for the symptoms observed in mice as well as in
humans. In addition and unexpectedly, the GABAA-receptor-
mediated transmission is also drastically reduced (90.9%) in the
tg271Q-300 transgenic animals. This points to an adaptational
interaction between the two inhibitory systems involved. Such
interactions at the organism level are suggested by anatomical,
clinical, and pharmacological evidence: (1) Both receptors often
colocalize in rat spinal cord (Bohlhalter et al., 1994), and their
transmitters are coreleased at many nerve endings (Jonas et al.,
1998). (2) Both glycine and GABAA receptors are clustered at the
synapses and require the presence of the receptor-associated
protein gephyrin for correct synaptic localization of the receptor
complexes (Essrich et al., 1998; Feng et al., 1998; Kneussel et al.,
1999). (3) Genetic GlyR disease in humans can be treated with
benzodiazepines, although with variable success (Ryan et al.,
1992). (4) The symptoms in SMS, an autoimmune disease asso-
ciated with antibodies against glutamic acid decarboxylase iso-
form 65, causing a dysfunction of the GABAergic system, resem-
ble the symptoms of genetic GlyR defects with respect to
electromyographic data (Stayer and Meinck, 1998). The recently
identified autoimmune reactivity against gephyrin in a patient
with SMS (Butler et al., 2000) might represent an example of an
acquired GlyR malfunction.
Starting to address the mechanism by which the glycinergic and
the GABAergic systems interact in our model, we found, at our
limits of resolution, no influence of overexpression of mutated or
unmutated GlyR 1 subunit on the binding of a GABAA-receptor
ligand on brain tissue. This result is in line with previous obser-
vations on the mouse mutant spa, in which GABAA receptor was
not reduced but rather slightly enhanced, suggesting compensa-
tory mechanisms at the receptor level (White and Heller, 1982).
It should be noted that our ligand-binding data do not exclude
possible changes in the subunit composition of GABAA receptors
or developmental changes in its subunit composition. They also
do not exclude extrasynaptic localization of the GABAA recep-
tors. However, downregulation of GABAA-receptor transmission
by the lack of GlyR function could take place at the level of
physiology, whereby postsynaptic and presynaptic mechanisms
are conceivable. Because it is hardly possible to address these
questions directly, evidence for presynaptic changes can be
gained by an analysis of miniature IPSCs and by an ANOVA of
triggered postsynaptic currents (Bekkers and Stevens, 1989; Ma-
linow and Tsien, 1990). Preliminary data point to a reduction of
presynaptic release in GABAergic synapses as well as to regula-
tory alterations on the postsynaptic side (our unpublished data).
Possible mechanisms affecting both the glycinergic- and GABAA-
receptor-mediated transmission at the presynaptic level could
involve factors important for the presynaptic transmitter release.
An interesting candidate for a shared function important in both
pathways could be the vesicular inhibitory amino acid transporter
(Sagne´ et al., 1997), which is responsible for the uptake of glycine
and GABA into synaptic vesicles (Burger et al., 1991; Dumoulin
et al., 1999). It is conceivable that lack of GlyR function will
affect the function of this transporter; this would also inhibit
presynaptic GABA uptake.
Additional studies of this animal model are necessary to clarify
these points. However, the data obtained thus far might have
significant consequences on therapeutic strategies not only of the
rare genetic GlyR defects, but also of the more frequent acquired
neuromotor deficiency caused by the dysfunction of GABAA
receptors (SMS).
Considering that, as we have shown previously (Hartenstein et
al., 1996; Becker et al., 2000), low expression of functional GlyR
is sufficient for glycinergic inhibition, gene therapy for genetic
GlyR defects should be possible, provided appropriate gene de-
livery technology is used. However, because of adverse effects of
overexpression or ectopic expression of a “healthy” gene, as seen
in the tg271R animals, such approaches require precise expres-
sion control. These tg271R animals might finally be useful to
investigate the recently raised issue of a potential role of glycin-
ergic transmission in neurodegeneration (Chen et al., 1999).
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